Aranjuez factory reduces its emissions index by 15 %


In 2021, the Ercros factory in Aranjuez reduced its overall accident frequency rate and its emissions index. At the same time, it improved the quality index of its products.

Specifically, between 2020 and 2021, the Aranjuez factory reduced the general accident frequency rate by 4.6%, which measures accidents between its own and external staff (with and without sick leave) for every million hours worked.

Last year this factory reduced its emissions index – which measures substances emitted into air and water and waste generation – by 14.7% compared to 2020 and 15.7% compared to the average of the last five years.

In terms of quality, the Aranjuez factory reduced its claims rate by 60.5% and improved it by 44.0% compared to the average of the last five years. This index measures the number of tons of products affected by customer complaints about the number of tons sold.

The Aranjuez facility has certified the management of occupational safety according to ISO 45001, quality management according to ISO 9001 and environmental management according to ISO 14001; and verified its greenhouse gas emissions according to ISO 14064.

The Ercros performance in all aspects of sustainability has earned it the Platinum classification in the international rating EcoVadis, obtaining a score of 84 out of 100 with which Ercros is among the 1% with the best compliance with good ESG practices (environmental, social and governance) of the 75,000 companies evaluated, and has obtained an A rating and 77 points out of 100 in the ESG Rating 2021 of the Spanish Institute of Financial Analysts. Likewise, the company has been certified as a CSR Company in the Excellence category, by the Responsible Care program of the global chemical sector.

Aranjuez factory forms the pharmacy division of Ercros and is intended to produce active pharmaceutical ingredients (APIs), mainly from the antibiotic family. The factory directly employs about 215 people and in 2021 had a turnover of more than 50 million euros and exported 95% of its sales, mainly to USA, EU, Middle East, and North Africa. It is the world's second largest manufacturer of fusidic acid and the third of fosfomycin.